News
Addex Therapeutics
ADXN · SWISS
$2.97+$0.0779 (+2.69%)TodayMarket closed ·
Prev close $2.89
Latest news
- News
Addex Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
- News
Earnings Scheduled For September 28, 2026
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
Addex Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
- News
Addex Therapeutics Q4 2025 Earnings Call Transcript
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- NewsAvi Kapoor
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- Press releaseGlobe Newswire
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsAvi Kapoor
S&P 500 Edges Higher; American Woodmark Shares Slide
- NewsAvi Kapoor
Crude Oil Dips; Addex Therapeutics Shares Spike Higher
- NewsAvi Kapoor
US Stocks Mixed; ScanSource Reports Weak Q4 Results
- NewsVandana Singh
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
- News
Market-Moving News for August 27th
- NewsAvi Kapoor
Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
- News
Addex And Indivior Choose Clinical Candidates From Their GABAB Positive Allosteric Modulator Research Partnership
- Press releaseGlobe Newswire
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
- Press releaseGlobe Newswire
Addex's Partner Discontinues ADX71149 development in Epilepsy
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.